S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.40
-0.06 (-2.44%)
(As of 02/3/2023 09:04 PM ET)
Add
Compare
Today's Range
$2.40
$2.46
50-Day Range
$1.97
$2.66
52-Week Range
$1.95
$3.18
Volume
28,500 shs
Average Volume
39,596 shs
Market Capitalization
$117.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MediciNova MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$15,870 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.20) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.04 out of 5 stars

Medical Sector

1014th out of 1,025 stocks

Pharmaceutical Preparations Industry

490th out of 498 stocks

MNOV stock logo

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings
11/10/2022
Today
2/05/2023
Next Earnings (Estimated)
2/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNOV
Employees
11
Year Founded
2000

Profitability

Net Income
$-10,130,000.00
Pretax Margin
-2,628,577.25%

Debt

Sales & Book Value

Annual Sales
$4.04 million
Book Value
$1.71 per share

Miscellaneous

Free Float
40,855,000
Market Cap
$117.72 million
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Yuichi Iwaki
    President, Chief Executive Officer & Director
  • Jason Kruger
    Chief Financial Officer
  • Kazuko Matsuda
    Director & Chief Medical Officer
  • Geoffrey G. O'Brien
    Vice President & Executive Officer
  • David H. Crean
    Chief Business Officer













MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings
or view top-rated stocks.

How have MNOV shares performed in 2023?

MediciNova's stock was trading at $2.05 at the start of the year. Since then, MNOV shares have increased by 17.1% and is now trading at $2.40.
View the best growth stocks for 2023 here
.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our MNOV earnings forecast
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings data on Thursday, November, 10th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02.

What other stocks do shareholders of MediciNova own?
What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a variety of institutional and retail investors. Top institutional investors include Capricorn Fund Managers Ltd (0.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends
.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $2.40.

How much money does MediciNova make?

MediciNova (NASDAQ:MNOV) has a market capitalization of $117.72 million and generates $4.04 million in revenue each year.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 2/6/2023 by MarketBeat.com Staff